# A Phase I/II Study of TRS005 in Combination With Cyclophosphamide, Doxorubicin, and Prednisone（T-CHP） in Previously Untreated Patients With CD20-positive DLBCL

> **NCT07035379** · PHASE1,PHASE2 · NOT_YET_RECRUITING · sponsor: **Zhejiang Teruisi Pharmaceutical Inc.** · enrollment: 66 (estimated)

## Conditions studied

- Diffuse Large B-Cell Lymphoma (DLBCL)

## Interventions

- **DRUG:** TRS005
- **DRUG:** Cyclophosphamide
- **DRUG:** Doxorubicin
- **DRUG:** Prednisolone

## Key facts

- **NCT ID:** NCT07035379
- **Lead sponsor:** Zhejiang Teruisi Pharmaceutical Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-09-01
- **Primary completion:** 2026-09-01
- **Final completion:** 2028-09-01
- **Target enrollment:** 66 (ESTIMATED)
- **Last updated:** 2025-08-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07035379

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07035379, "A Phase I/II Study of TRS005 in Combination With Cyclophosphamide, Doxorubicin, and Prednisone（T-CHP） in Previously Untreated Patients With CD20-positive DLBCL". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT07035379. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*